Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:41:38.704Z.
Calculation as of: 2026-10-06T16:41:38.704Z.
Quote observation: 2026-10-06T16:40:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b8816454c8f8663c3bedc847144af8f107147f6cc2e90a46c8541497c2a45775
PE RATIO
N/A
Market Cap
$5.74B
PE Ratio
76.92
TTM Avg
136.52
3Y Avg
215.24
5Y Avg
141.48
Market Cap
$5.93B
PE Ratio
31.62
TTM Avg
54.86
3Y Avg
51.97
5Y Avg
46.21
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CG Oncology Inc. (CGON) | $5.71B | N/A | N/A | N/A | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.74B | 76.92 | 136.52 | 215.24 | 141.48 |
| RadNet, Inc. (RDNT)vs › | $5.54B | N/A | 670.99 | 322.02 | 261.00 |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.93B | 31.62 | 54.86 | 51.97 | 46.21 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.95B | N/A | N/A | N/A | N/A |
| GRAIL Inc. (GRAL)vs › | $6.06B | N/A | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.33B | 33.50 | 29.46 | 43.55 | 46.11 |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | N/A | 8.39 | 8.39 | 8.39 |
| Sotera Health Company (SHC)vs › | $5.28B | 32.32 | 70.23 | 85.34 | 112.40 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$64.77
Forward EPS (Est.)
$-3.32
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
